In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Centessa Pharmaceuticals plc

http://www.centessa.com/

Latest From Centessa Pharmaceuticals plc

Alys Puts Skin In The Dermatology Game With $100m Launch

Having adopted a similar model to set up Centessa, investment firm Medicxi is merging six of its portfolio companies to create an ambitious immuno-dermatology group.

Dermatology Financing

Deal Watch: Vanda Buys US, Canadian Rights To J&J’s Ponvory

Plus deals involving Bristol Myers Squibb/Avidity, Aexon/NLS, Boehringer Ingelheim/Phenomic AI, AnaptysBio/Centessa and Biodexa/Adhera/Melior.

Deal Watch Business Strategies

Pfizer’s Marstacimab Wins In Phase III, But Caution On Market Position, Clotting Remain

The drug showed efficacy in hemophilia A and B with no sign of clots, an issue that historically has dogged anticoagulation agents, but it remains unclear whether that advantage will hold.

Clinical Trials Blood & Coagulation Disorders

Scrip Asks…What Does 2023 Hold For Biopharma? Part 6: Artificial Intelligence

The biopharma industry may not have been the fastest adopter of artificial intelligence, but its vast potential means companies of every shape and size know they cannot ignore it. Executives, advisors and investors share their predictions around the impact of AI in 2023.

Scrip Asks Artificial Intelligence
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Other Names / Subsidiaries
    • Centessa Pharmaceuticals Ltd.
UsernamePublicRestriction

Register